Background:
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can cause ICI myocarditis (ICIM), a potentially fatal complication driven by aberrant CD8
+
T-cell responses. Current therapies reduce cardiac inflammation but may compromise anti-tumor immunity. We observed that CXCR3 inhibitio...
Yin Sun, M. R. Vitale, Tanvi Shankar et al.· Circulation· 0 citations
Although immune checkpoint inhibitors have improved cancer outcomes, their use can trigger autoimmune toxicities affecting essentially any organ system. In the cardiovascular system, these immune-related adverse events can manifest as myocarditis, pericarditis, accelerated atherosclerosis, vasculitis, arrhythmias, and...
Kerry L. Reynolds, A.-C. Villani, Z. Drobni et al.· JACC CardioOncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.